Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

MEN1309

Monoclonal human antibody (ADC)

ONCOLOGY

Logo Shuttle 1309

CURRENT DEVELOPMENT PHASE: lymphomas and solid tumors

preclinicl
phase i
phase ii
phase iii
pre-registration
post-registration

MEN1309 is a conjugated antibody combined with a potent cytotoxic agent (ADC).

The target of MEN1309 is a membrane protein which is over-expressed by tumor cells of type-B non-Hodgkin's lymphoma and solid tumors of different histological types (such as certain subgroups of breast cancer).

Through the antigen-binding, MEN1309 is internalized in cancer cells where it releases the toxin. Through this mechanism, MEN1309 exerts a potent and selective cytotoxic activity on tumor cells.

The biotechnological process for the production of MEN1309 has been developed at Menarini Biotech in Pomezia.

MEN1309 has demonstrated an excellent anti-tumoral activity in different experimental xenograft models.

A phase I clinical trial SHUTTLE, in oncological patients is active in 4 European Countries (BE,ES, UK, IT) to identify the Maximum Tolerated Dose of the MEN1309

VISIT OUR CLINICAL TRIALS DATABASE

 

 

THERAPEUTIC AREAS

Discover all of Menarini's products marketed in Italy. Read More »

DIAGNOSTICS

 

Advanced Technology

READ MORE »

THE MENARINI GROUP

Discover the leading Italian pharmaceutical company in the world. Read More »

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more